Replies to post #13 on Trius Therapeutics, Inc. (TSRX)

[EquityTrader]

See them now...Reading... :D

[EquityTrader]

For the record TSRX beat analyst estimates of $2.4 Million in Revenue for the quarter with $2.7 million. EPS was slightly off compared to estimates, but with an average analyst opinion of $9.17 per share I think we can shoot up on Friday a little. Would expect some reiteration and or increase to buy ratings with Phase 3 trials underway. Good thing is they are getting government funding. :D


3 Strong Buy Ratings
3 Buy Ratings


...the last rating added this month was a "STRONG BUY"

Looking for that trend to continue. I believe $8-10 is not too far off. Hopefully, the volume will help some of the mid-larger brokerages take note and give this a buy rating. Another strong buy rating for a larger brokerage house and this could go $10+ in a heartbeat. Reminds me of what HOKU did a few years ago when it went from $4 to $15+ in a matter of 2-3 weeks. Right company at the right time.

[EquityTrader]

Hope you took some profits here...up a bit too fast. Once it stabalizes it should come back up.

[EquityTrader]

Might be time to look at reentering this again.

[EquityTrader]

Dang, I should have bought a bit more when it was under $7.